Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine tenth anniversary update: the progress continues

P E Stokes1, A Holtz

  • 1Payne Whitney Clinic, New York Hospital-Cornell University Medical Center, New York, USA.

Clinical Therapeutics
|January 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posterolateral plate fixation with Pantalarlock® is more stable than nail fixation in tibiotalocalcaneal arthrodesis in a biomechanical cadaver study.

Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons·2019
Same author

[A rare differential diagnosis of acute appendicitis].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2015
Same author

Microtubule-associated protein 2 as a sensitive marker for dendrite lesions after spinal cord trauma: an immunohistochemical study in the rat.

Restorative neurology and neuroscience·2011
Same author

Hypercortisolemia decreases dexamethasone half-life in rabbit.

Journal of psychiatric research·2002
Same author

New psychopharmacologic treatment strategies.

Annals of internal medicine·2001
Same author

Lithium isotopes: differential effects on renal function and histology.

Bipolar disorders·2001

Fluoxetine is a well-established treatment for depression and other disorders, offering proven efficacy and a favorable side-effect profile. Its extended half-life prevents withdrawal symptoms, making it a preferred choice for long-term management.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Fluoxetine has been a cornerstone pharmacotherapy for major depressive disorder for a decade.
  • Selective serotonin reuptake inhibitors (SSRIs) are a primary treatment modality for depression and related conditions.

Purpose of the Study:

  • To review the clinical application of fluoxetine over the past five years.
  • To evaluate fluoxetine's efficacy, safety, and pharmacoeconomic profile in various patient populations.

Main Methods:

  • Review of clinical studies and pharmacoeconomic data on fluoxetine.
  • Analysis of fluoxetine's efficacy in depression subgroups, eating disorders, and obsessive-compulsive disorder (OCD).

Main Results:

  • Fluoxetine demonstrates efficacy comparable to tricyclic antidepressants (TCAs) with easier administration and a benign side-effect profile.

Related Experiment Videos

  • Effective in treating depression, bulimia, and OCD, with notable success in special populations like children and adolescents.
  • Its extended half-life minimizes withdrawal symptoms, unlike short-half-life antidepressants, reducing relapse rates and healthcare utilization.

    • Conclusions:

    • Fluoxetine remains a highly effective and safe pharmacotherapy for depression and other psychiatric disorders.
    • Its unique pharmacokinetic profile offers advantages in patient compliance and long-term management, outweighing potential cost differences.
    • Fluoxetine is a valuable therapeutic option for diverse patient groups, including those with comorbid medical conditions and younger populations.